Veru (STU:FMW0) OCF Margin %: 0.00% (As of Mar. 2026)


STU:FMW0 Veru Inc STU:FMW0
28 GF Score
Price €3.11
! 2 Warning Signs
View Full Analysis

What is Veru OCF Margin %?

Veru STU:FMW0 28 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:FMW0 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 954 Biotechnology companies, Veru ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Veru's Cash Flow from Operations for the three months ended in Mar. 2026 was €-7.71 Mil. Veru's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Veru's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Veru's current OCF Yield % is -53.05%.

The historical rank and industry rank for Veru's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Veru was 7.20%. The lowest was -540.06%. And the median was -21.34%.

STU:FMW0's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Veru OCF Margin % Related Terms

Veru OCF Margin % Historical Data

* Premium members only.

The historical data trend for Veru's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru OCF Margin % Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.42 -120.71 -540.07 0.00 0.00

Veru Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:FMW0
28GF Score
Veru Inc STU:FMW0
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Veru's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-25.597/0
= %

Veru's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.711/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Veru (STU:FMW0) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Veru and its competitors. According to the industry distribution chart, Veru ranks #999999 out of 954 companies in the Biotechnology industry.
Is Veru's OCF Margin % too high?
Veru's current OCF Margin % is 0.00%. Based on the distribution chart, Veru ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veru has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Veru's OCF Margin % compare to AURX and PDSB?
According to the Biotechnology industry distribution chart, Veru ranks #999999 out of 954 companies for OCF Margin %. This places Veru in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Veru and its competitors. Veru's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (STU:FMW0) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Veru's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Veru (STU:FMW0), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Other Exchanges VERU:USA
Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
28GF Score

Get the complete analysis for STU:FMW0

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.11
Price